Art. 28 Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 20…

In forcesince 2 Jul 2012cited 12×
1.

The obligations of marketing authorisation holders and of Member States laid down in Articles 107 and 107a of Directive 2001/83/EC shall apply to the recording and reporting of suspected adverse reactions for medicinal products for human use authorised in accordance with this Regulation.

2.

The obligations of marketing authorisation holders laid down in Article 107b of Directive 2001/83/EC and the procedures under Article 107b and Article 107c of that Directive shall apply to the submission of periodic safety update reports, the establishment of Union reference dates and changes to the frequency of submission of periodic safety update reports for medicinal products for human use authorised in accordance with this Regulation.

The provisions applicable to the submission of periodic safety update reports laid down in the second subparagraph of Article 107c(2) of that Directive shall apply to holders of marketing authorisations which were granted before 2 July 2012 and for which the frequency and dates of submission of the periodic safety update reports are not laid down as a condition to the marketing authorisation until such time as another frequency or other dates of submission of the reports are laid down in the marketing authorisation or are determined in accordance with Article 107c of that Directive.

3.

The assessment of the periodic safety update reports shall be conducted by a rapporteur appointed by the Pharmacovigilance Risk Assessment Committee. The rapporteur shall closely collaborate with the rapporteur appointed by the Committee for Medicinal Products for Human Use or the Reference Member State for the medicinal products concerned.

The rapporteur shall prepare an assessment report within 60 days of receipt of the periodic safety update report and send it to the Agency and to the members of the Pharmacovigilance Risk Assessment Committee. The Agency shall send the report to the marketing authorisation holder.

Within 30 days of receipt of the assessment report, the marketing authorisation holder and the members of the Pharmacovigilance Risk Assessment Committee may submit comments to the Agency and to the rapporteur.

Following the receipt of the comments referred to in the third subparagraph, the rapporteur shall within 15 days update the assessment report taking into account any comments submitted, and forward it to the Pharmacovigilance Risk Assessment Committee. The Pharmacovigilance Risk Assessment Committee shall adopt the assessment report with or without further changes at its next meeting and issue a recommendation. The recommendation shall mention the divergent positions with the grounds on which they are based. The Agency shall include the adopted assessment report and the recommendation in the repository set up under Article 25a, and forward both to the marketing authorisation holder.

4.

In the case of an assessment report that recommends any action concerning the marketing authorisation, the Committee for Medicinal Products for Human Use shall, within 30 days of receipt of the report by the Pharmacovigilance Risk Assessment Committee, consider the report and adopt an opinion on the maintenance, variation, suspension or revocation of the marketing authorisation concerned, including a timetable for the implementation of the opinion. Where this opinion of the Committee for Medicinal Products for Human Use differs from the recommendation of the Pharmacovigilance Risk Assessment Committee, the Committee for Medicinal Products for Human Use shall attach to its opinion a detailed explanation of the scientific grounds for the differences together with the recommendation.

Where the opinion states that regulatory action concerning the marketing authorisation is necessary, the Commission shall adopt a decision to vary, suspend or revoke the marketing authorisation. Article 10 of this Regulation shall apply to the adoption of that decision. Where the Commission adopts such a decision, it may also adopt a decision addressed to the Member States pursuant to Article 127a of Directive 2001/83/EC.

5.

In the case of a single assessment of periodic safety update reports concerning more than one marketing authorisation in accordance with Article 107e(1) of Directive 2001/83/EC which includes at least one marketing authorisation granted in accordance with this Regulation, the procedure laid down in Articles 107e and 107g of that Directive shall apply.

6.

The final recommendations, opinions and decisions referred to in paragraphs 3 to 5 of this Article shall be made public by means of the European medicines web-portal referred to in Article 26.

The 10 that are cited most themselves, of 12.

  • Commission Regulation (EC) No 658/2007 of 14 June 2007 concerning financial penalties fo…1Law

    … от лекарствени продукти за хуманна употреба, в съответствие с член 28, параграф 1 от Регламент (ЕО) № 726/2004 във връзка с член 107 от …

  • Commission Regulation (EU) No 488/2012 of 8 June 2012 amending Regulation (EC) No 658/20…1Law

    … от лекарствени продукти за хуманна употреба, в съответствие с член 28, параграф 1 от Регламент (ЕО) № 726/2004 във връзка с член 107 от …

  • Judgment of the Court (Grand Chamber) of 23 January 2018. F. Hoffmann-La Roche Ltd and Others v Autorità Garante della Concorrenza e del MerDecision

    … 1235/2010 erstattet. Artikel 28, stk. 4, i forordning nr. 726/2004, som ændret, er affattet således: »I tilfælde af, at en vurderingsrapport anbefaler en foranstaltning for så vidt angår markedsføringstilladelsen, behandler Udvalget …

    23 Jan 2018 · 62016CJ0179

  • Regulation (EU) 2024/568Law

    … de sécurité visés à l’article 107 sexies et à l’article 107 octies de la directive 2001/83/CE et à l’article 28 du règlement (CE) no 726/2004. La rémunération pour le rapporteur s’élève à 17300 EUR. 14.2. Lorsque deux …

  • Commission Regulation (EU) No 488/2012 of 8 June 2012 amending Regulation (EC) No 658/20…1Law

    … obligation to record and report suspected adverse reactions for medicinal products for human use, in accordance with Article 28(1) of Regulation (EC) No 726/2004 read together with Article 107 of Directive 2001/83/EC; the obligation to …

  • Gesetz über den Verkehr mit Arzneimitteln97Law

    … entgegen Artikel 28 Absatz 1 der Verordnung (EG) Nr. 726/2004 in Verbindung mit Artikel 107 Absatz 1 Unterabsatz 2 der Richtlinie 2001/83/EG nicht dafür sorgt, dass eine Meldung an einer dort genannten Stelle verfügbar ist. (2c) …

  • Opinion of Advocate General Saugmandsgaard Øe delivered on 21 September 2017. F. Hoffmann-La Roche Ltd and Others v Autorità Garante della CDecision

    That is the case whether or not there is continuing scientific uncertainty regarding the safety of a medicinal products. In my opinion, omitting to state that the risks created by using the medicine are uncertain, or exaggerating such …

    21 Sep 2017 · 62016CC0179

  • Opinion of Advocate General Saugmandsgaard Øe delivered on 25 July 2018. Novartis Farma SpA v Agenzia Italiana del Farmaco (AIFA) and OthersDecision

    Furthermore, Articles 21 to 29 of that regulation provide for a system of pharmacovigilance for the medicinal products authorised at EU level.

    25 Jul 2018 · 62017CC0029

  • Commission Regulation (EC) No 658/2007 of 14 June 2007 concerning financial penalties fo…1Law

    … obligation to record and report suspected adverse reactions for medicinal products for human use, in accordance with Article 28(1) of Regulation (EC) No 726/2004 read together with Article 107 of Directive 2001/83/EC; the obligation to …

  • Judgment of the General Court (Fourth Chamber) of 11 February 2026. Mylan Ireland Ltd v European Commission.Decision

    Thirdly, the applicant submits that, in the light of Article 81(2) of Regulation No 726/2004, an MA may be revoked only in the circumstances described in Article 28(4) of Regulation No 726/2004, that is to say, following safety concerns. A …

    11 Feb 2026 · 62023TJ1181